Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Oct 23 - Oct 28
The DELIVER trial randomized 6,263 patients with symptomatic HF, 74% of whom had NYHA class II symptoms, either with HF with moderately reduced ejection fraction (HFmrEF
*Note: Results may vary - no outcome is guaranteed
Topicals are best used as a secondary support rather than a primary source
Investors including Bain Capital backed the company's thesis that next-generation multi-receptor agonists and oral small molecules could capture meaningful share from first-generation agents
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al
US$ 24.34
US$ 21.05
US$ 28.06
US$ 27.70
US$ 20.84
